

Shuai Mao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8903874/publications.pdf>

Version: 2024-02-01

25
papers

344
citations

759233

12
h-index

888059

17
g-index

27
all docs

27
docs citations

27
times ranked

338
citing authors

#	ARTICLE	IF	CITATIONS
1	Phytoestrogen, tanshinone IIA diminishes collagen deposition and stimulates new elastogenesis in cultures of human cardiac fibroblasts. <i>Experimental Cell Research</i> , 2014, 323, 189-197.	2.6	35
2	Traditional Chinese medicine, Danlou tablets alleviate adverse left ventricular remodeling after myocardial infarction: results of a double-blind, randomized, placebo-controlled, pilot study. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 447.	3.7	28
3	Tongguan Capsule Mitigates Post-myocardial Infarction Remodeling by Promoting Autophagy and Inhibiting Apoptosis: Role of Sirt1. <i>Frontiers in Physiology</i> , 2018, 9, 589.	2.8	27
4	Sodium tanshinone IIA sulfonate for reduction of periprocedural myocardial injury during percutaneous coronary intervention (STAMP trial): Rationale and design. <i>International Journal of Cardiology</i> , 2015, 182, 329-333.	1.7	21
5	Nanoparticle-mediated delivery of Tanshinone IIA reduces adverse cardiac remodeling following myocardial infarctions in a mice model: role of NF- κ B pathway. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 707-716.	2.8	21
6	Rationale and Design of Sodium Tanshinone IIA Sulfonate in Left Ventricular Remodeling Secondary to Acute Myocardial Infarction (STAMP-REMODELING) Trial: A Randomized Controlled Study. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 535-542.	2.6	19
7	Tanshinone IIA inhibits angiotensin II induced extracellular matrix remodeling in human cardiac fibroblasts – Implications for treatment of pathologic cardiac remodeling. <i>International Journal of Cardiology</i> , 2016, 202, 110-117.	1.7	18
8	iPSC – endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	17
9	Sodium tanshinone IIA sulfonate prevents the adverse left ventricular remodelling: Focus on polymorphonuclear neutrophil – derived granule components. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 4592-4600.	3.6	16
10	Baduanjin Exercise Prevents post-Myocardial Infarction Left Ventricular Remodeling (BE-PREMIER) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Therapy, 2016, 30, 315-322.	2.6	15
11	Exosome CTLA-4 Regulates PTEN/CD44 Signal Pathway in Spleen Deficiency Internal Environment to Promote Invasion and Metastasis of Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 757194.	3.5	15
12	Effect of Danlou Tablet (ä, 1è'Çç%#) on peri-procedural myocardial injury among patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndrome: A study protocol of a multicenter, randomized, controlled trial. <i>Chinese Journal of Integrative Medicine</i> , 2015, 21, 662-666.	1.6	14
13	Exploration of Multiple Signaling Pathways Through Which Sodium Tanshinone IIA Sulfonate Attenuates Pathologic Remodeling Experimental Infarction. <i>Frontiers in Pharmacology</i> , 2019, 10, 779.	3.5	13
14	Beneficial Effects of Baduanjin Exercise on Left Ventricular Remodelling in Patients after Acute Myocardial Infarction: an Exploratory Clinical Trial and Proteomic Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 21-32.	2.6	13
15	Prevention of endotoxin-induced cardiomyopathy using sodium tanshinone IIA sulfonate: Involvement of augmented autophagy and NLRP3 inflammasome suppression. <i>European Journal of Pharmacology</i> , 2021, 909, 174438.	3.5	12
16	In – depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10042-10051.	3.6	11
17	Efficacy of Sodium Tanshinone IIA Sulfonate in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Controlled, Randomized Trial. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 321-329.	2.6	11
18	Fat – 1 transgenic mice rich in endogenous omega – 3 fatty acids are protected from lipopolysaccharide – induced cardiac dysfunction. <i>ESC Heart Failure</i> , 2021, 8, 1966-1978.	3.1	10

